Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.51 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.51 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.48 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28753879 | 0.89 | MAPT (0.51) | TXNRD1TXNRD3TXNRD2ALDH1A1CYP1A2 | |
| SCHEMBL27619441 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL31067258 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL646725 | 0.79 | TTR (0.53) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL29659762 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL1438861 | 0.79 | PLAU (0.53) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL16289020 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL516896 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL28234952 | 0.79 | ALDH1A1 (0.51) | TTRTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL8541741 | 0.78 | ALDH1A1 (0.58) | TTRALDH1A1CYP1A2CYP3A4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791426-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4359403-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117616021-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2021160087-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021018009-A1 | EGFR INHIBITOR, COMPOSITION, AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | HYUNDAI PHARM. IND. CO., LTD. (KR) | 2005-07-28 | — | — | US | disclosed |
| WO-2003082286-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHEMON INC. (KR) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | TTR 3836/4885TXNRD1 971/4885TXNRD3 1548/4885 |
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | SLC18A2, SLC6A4, SLC6A2 | TTR 2562/4885TXNRD1 707/4885TXNRD3 1110/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | TTR 1958/4885TXNRD1 254/4885TXNRD3 215/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | TTR 1491/4885TXNRD1 3280/4885TXNRD3 3713/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | TTR 996/4885TXNRD1 2696/4885TXNRD3 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.